Home / Resources / Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

Report
Clinical
Preview Report Cover for Pharma R&D Annual Review 2024 Supplement: New Active Substances Launched During 2023

2023年、医薬品業界では、90品目（1品目は2つのNASを含む合剤）、91品目のNASが上市された。NASの上市数では過去2番目の年となった。

進化を続けるがん治療において、標的療法は革新の原動力となる技術であり続けている。
スティーブ・ウォーランド、eFFECTORセラピューティクスCEO
Related products
Getting the full drug RandD landscape
Pharmaprojects
世界的な医薬品研究開発の状況を追跡し、分析するための業界標準
Surfacing insights for a successful clinical trial
Trialtrove
臨床試験の戦略、設計、実施のための頼りになる情報リソース
Analyst visualizing the drug development process on screen
Biomedtracker
医薬品開発パイプラインのリアルタイム追跡と分析

Related resources

Citeline Clinical Infographic: A Promising Rebound Selected Insights from the Annual Clinical Trials Roundup: 2024 Edition
OCT 10, 2024
Infographic
Clinical

The Annual Clinical Trials Roundup 2024 Edition: Promising Road to Recovery

The rebound in clinical trial starts in 2023 signals a return to form after last year’s decline.

A variety of pills and tablets arranged neatly on a wooden table surface
OCT 09, 2024
Report
商業化支援サービス

Key Potential Drug Launches in 2025

Biomedtracker’s Key Potential Drug Launches in 2025 report provides a longer-term look at some key late-stage drugs projected to hit the market in 2025.

AI
OCT 11, 2024
Whitepaper
Clinical

製薬業界における AI: リスク、リターン、そして今後の展望

AI is being used to streamline and accelerate each step of the drug development process from research through approval and marketing.

View all